Report Library
All Reports
ADPD Alzheimer's Disease Pulse
March 19, 2015
We performed a 5-question survey of 25 neurologists in the US to gauge current familiarity with Alzheimer’s Disease (AD) biomarkers and drugs in clinical development for disease modification.
Drugs covered include: BIIB037/BART (BIIB), Solanezumab (LLY), Pioglitazone (Takeda), BAN2401 (ESALY/BIIB), MK-8931 (MRK).
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all
reports
and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call
BioMedTracker
Client Services at (858) 200-2357.
To purchase the AD survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
To purchase the AD survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: |
Alzheimer's Disease (AD)
Alzheimer's Disease - Imaging |
Additional Resources: